MegaPro Biomedical Co (ROCO:6827) ROC %: -97.31% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6827 MegaPro Biomedical Co Ltd ROCO:6827
32 GF Score
Price NT$10.70
View Full Analysis

What is MegaPro Biomedical Co ROC %?

MegaPro Biomedical Co ROCO:6827 -2.28% 32 ROC % is -97.31% as of Dec. 2025. GuruFocus rates ROCO:6827 with a GF Score™ of 32/100.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. MegaPro Biomedical Co's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was -97.31%.

As of today (2026-07-18), MegaPro Biomedical Co's WACC % is 9.42%. MegaPro Biomedical Co's ROC % is -101.77% (calculated using TTM income statement data). MegaPro Biomedical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.

MegaPro Biomedical Co  (ROCO:6827) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, MegaPro Biomedical Co's WACC % is 9.42%. MegaPro Biomedical Co's ROC % is -101.77% (calculated using TTM income statement data). MegaPro Biomedical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

MegaPro Biomedical Co ROC % Related Terms

MegaPro Biomedical Co ROC % Historical Data

* Premium members only.

The historical data trend for MegaPro Biomedical Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MegaPro Biomedical Co ROC % Chart

MegaPro Biomedical Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial -49.09 -55.16 -83.56 -131.60 -86.33

MegaPro Biomedical Co Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -78.40 -135.72 -158.21 -128.47 -97.31
ROCO:6827
32GF Score
MegaPro Biomedical Co Ltd ROCO:6827
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MegaPro Biomedical Co ROC % Calculation

MegaPro Biomedical Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-119.586 * ( 1 - 0% )/( (123.071 + 153.983)/ 2 )
=-119.586/138.527
=-86.33 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=224.315 - 13.568 - ( 87.676 - max(0, 16.776 - 174.569+87.676))
=123.071

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=278.917 - 12.65 - ( 112.284 - max(0, 15.938 - 257.707+112.284))
=153.983

MegaPro Biomedical Co's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-111.644 * ( 1 - 0% )/( (75.466 + 153.983)/ 2 )
=-111.644/114.7245
=-97.31 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=162.363 - 24.379 - ( 62.518 - max(0, 27.673 - 120.226+62.518))
=75.466

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=278.917 - 12.65 - ( 112.284 - max(0, 15.938 - 257.707+112.284))
=153.983

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -97.31% mean?
MegaPro Biomedical Co (ROCO:6827) has a ROC % of -97.31% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on MegaPro Biomedical Co and its competitors.
Is MegaPro Biomedical Co's ROC % too high?
MegaPro Biomedical Co's current ROC % is -97.31%. Overall, MegaPro Biomedical Co has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does MegaPro Biomedical Co's ROC % compare to VRTX and REGN?
MegaPro Biomedical Co's ROC % of -97.31% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on MegaPro Biomedical Co and its competitors. MegaPro Biomedical Co's current ROC % is -97.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MegaPro Biomedical Co stock overvalued right now?
MegaPro Biomedical Co (ROCO:6827) has a current ROC % of -97.31%. The current ROC % is -97.31%. MegaPro Biomedical Co's overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For MegaPro Biomedical Co (ROCO:6827), the current ROC % is -97.31% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MegaPro Biomedical Co Business Description

Address No. 66, Shengyi 5th Road, 10F-1, Hsinchu Science Park, Hsinchu, TWN, 31040
MegaPro Biomedical Co Ltd is a nanomedicine development company. The Company's only reportable operating segment is the Drug Application Development segment, which is engaged in the development of nano-iron oxide IOP drugs.
32GF Score

Get the complete analysis for ROCO:6827

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$10.70
Price